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ABSTRACT. Type 1 diabetes mellitus (T1D) is an organ-specific autoimmune 
disease characterized by T-cell mediated self-destruction of insulin-
producing β cells in the pancreas. T1D patients are prone to develop other 
glandular autoimmune disorders, such as autoimmune thyroid disease that 
occurs simultaneously with autoimmune polyglandular syndrome type III 
(APSIII). Signal transducer and activator of transcription 4 (STAT4) is a well-
known regulator of proinflammatory cytokines, and interferon-induced with 
helicase C domain 1 (IFIH1) is activated in the interferon type I response. 
Both genes have been examined separately in autoimmune diseases and, 
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in this study, we assessed their joint role in T1D and APSIII. We conducted 
a case-control study, enrolling 173 T1D patients and 191 healthy controls 
from northeastern Brazil, to assess the distribution of the rs7574865 and 
rs3024839 SNPs in STAT4 and the rs3747517 and rs1990760 SNPs in 
IFIH1 in T1D and APSIII patients. Additionally, we conducted a meta-
analysis with the rs7574865 SNP in STAT4 (1392 T1D patients and 1629 
controls) and the rs1990760 SNP in IFIH1 (25092 T1D patients and 28544 
controls) to examine their association with T1D. Distribution of STAT4 and 
IFIH1 allelic frequencies did not show statistically significant differences 
between T1D patients and controls in our study population; however, the 
meta-analysis indicated that SNPs in STAT4 and IFIH1 are associated with 
T1D worldwide. Our findings indicate that although STAT4 and IFIH1 SNPs 
are not associated with T1D in a Brazilian population, they might play a role 
in susceptibility to T1D on a larger worldwide scale.
Key words: STAT4; IFIH1; Autoimmune polyglandular syndrome type III;
SNP; Type 1 diabetes
INTRODUCTION
Type 1 diabetes mellitus (T1D) is an organ-specific autoimmune disease characterized by 
T cell-mediated attack of the insulin-producing β cells in the pancreas, leading to insulin deficiency 
(Gillespie, 2006). T1D is a multifactorial disease caused by genetic and environmental factors, as 
well as their interaction, that play a key role in the development of the disease. In up to one-quarter 
of T1D patients, an unbalanced immune system leads to autoimmune polyglandular syndrome type 
III (APSIII), which is characterized by the simultaneous occurrence of autoimmune thyroid disease 
(AITD) and sex bias (adult females are preferentially affected) (Kordonouri et al., 2002; Dittmar 
and Kahaly, 2010). Furthermore, patients with APSIII may also be diagnosed with celiac disease 
(CD). Despite the genetic variation in human leukocyte antigen (HLA) and its involvement in T1D 
development, new genes have been identified as potentially important in disease’s susceptibility 
and modulation outside HLA range (Gillespie, 2006; Liang et al., 2012).
Signal transducer and activator of transcription 4 (STAT4) is a latent cytoplasmic 
transcription factor activated by phosphorylation in response to proinflammatory cytokines, 
such as interleukin (IL)-12, IL-15, and IL-23 (Levy and Darnell, 2002). STAT4 is involved in T 
helper 1 (Th1) cell regulation and is expressed in activated peripheral blood monocytes, dendritic 
cells, and macrophages at inflammation sites. Additionally, STAT4 mediates IL-12 signaling, 
which modulates Th1 cell differentiation and proliferation, interferon-γ (INF-γ) production, and 
development of T helper 17 (Th17) cells (Kobayashi et al., 2008; Zervou et al., 2008). Since Th1 
cells are critical effectors of chronic inflammation disorders, STAT4 could play a pivotal role in the 
pathogenesis of immune diseases (Kobayashi et al., 2008; Zervou et al., 2008; Bi et al., 2013; 
Zheng et al., 2013). In fact, single nucleotide polymorphisms (SNPs) within STAT4 (chromosome 
location: 2q32.2-q32.3) have been reported to be associated with increased risk for several 
autoimmune diseases (Liang et al., 2012), including rheumatoid arthritis (RA) (Stark et al., 2009), 
systemic lupus erythematosus (SLE) (Kobayashi et al., 2008), and Sjögren’s syndrome (SS) 
(Palomino-Morales et al., 2010).
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Viral infections have been implicated as triggers in autoimmune disorders in T1D (Jun 
and Yoon, 2001; Salminen et al., 2003). Interferon-induced with helicase C domain 1 (IFIH1; 
gene located at chromosome 2q24), also known as MDA5, activates the type I interferon (IFN-I) 
pathway and pro-inflammatory cytokines by its CARD domains after detecting double-stranded 
RNA viruses (Chistiakov, 2010). Enterovirus infections, particularly coxsackievirus B4 strains, 
are known to be T1D-associated; therefore, IFIH1 may play an important role in the development 
of T1D and its autoimmune-related disorders (Jaïdane et al., 2009). Interestingly, during IFN-I 
activation, IFIH1 and STAT4 share a common pathway and, since both genes are known to be 
associated with T1D (Zheng et al., 2013), one can hypothesize that defects in both genes may 
increase susceptibility to disease compared to defects in just one gene, resulting in a cumulative 
effect of genetic mutations.
In this study, we investigated the single nucleotide polymorphisms (SNPs) rs7574865 
(G > T) and rs3024839 (T > C) in STAT4 and rs3747517 (C > T) and rs1990760 (C > T) in IFIH1 
and their link to T1D and APSIII susceptibility in a northeast Brazilian population. Additionally, 
we performed a meta-analysis for the rs7574865 and rs1990760 SNPs in T1D predisposition.
MATERIAL AND METHODS
Patients and control subjects
We performed a case-control study in T1D patients from Pernambuco State in northeast 
Brazil. We enrolled 173 T1D patients ranging in age from 0 to 18 years at diagnosis, with an 
age of 7.3 ± 4.1 (means ± SD) years at disease onset. The patients attended one of three 
pediatric endocrinology departments in the public healthcare system in Recife, Brazil (Instituto 
de Medicina Integral Professor Fernando Figueira, Hospital da Restauração and Hospital das 
Clínicas). A consent form was obtained from all patients (or their legal representative) enrolled 
in this study. T1D patients were diagnosed according to American Diabetes Association (ADA) 
criteria and classified as T1D from clinical and pathological presentation (Gabir et al., 2000).
From the T1D patient group, 47 (27.2%) were diagnosed with APSIII. AITD was diag-
nosed using antibodies against thyroperoxidase (anti-TPO) and detection was performed us-
ing chemiluminescence (Immulite anti-TPO, Diagnostic Products Co., Los Angeles, CA, USA) 
following the manufacturer instructions. The individuals positive for TPO (titer exceeding 35 
IU/mL, according to indications provided by the manufacturer) were considered as present-
ing AITD. The control group consisted of 191 healthy unrelated blood donors from the same 
geographic region with no history of autoimmune or chronic disease. The age of the control 
group ranged from 16 to 72 years and the means ± SD age was 38.8 ± 14.7 years. This study 
was carried out with advanced approval from the local Ethics Committee (IMIP Nos. 762/2006 
and 1717/2010).
Genotyping
Genomic DNA was obtained from whole blood and the extraction protocol was performed 
according to the manufacturer instructions (Wizard Genomic DNA Purification Kit; Promega, 
Madison, MA, USA). The DNA was stored at -20°C until analysis. The SNPs assessed in this study 
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have frequently been described in the literature: rs7574865 (G > T) from intron 3, rs3024839 (T > 
C) from exon 4 in STAT4, rs3747517 (C > T) in exon 13, and rs1990760 (C > T) in exon 15 of IFIH1. 
Genotyping was performed using commercially available Taqman probes and the ABI7500 real-
time PCR system (Applied Biosystems, Foster City, CA, USA). The allelic discrimination protocol 
was performed as recommended by the manufacturer and analyzed using SDS 2.3 software 
(Applied Biosystems).
Statistics and meta-analysis
Association analyses were performed by the chi-squared (χ2) test with continuity 
correction, and the odds ratio (OR) and 95% confidence intervals (CI) were calculated using the 
Fisher test. For the meta-analysis, we searched peer-reviewed articles published between 2003 
and 2015 (last search performed in July 2015) using logical equations with the following key 
words on PubMed and Web of Knowledge: “[(IFIHI or MDA5) and T1D]” or “(STAT4 and T1D)”. 
We selected only case-control studies with the allele counts available for both SNPs analyzed 
(rs7574865 and rs1990760). The meta-analysis tests were carried out using the “Metafor” 
package (Viechtbauer, 2010). When the P value from the Cochran Q test for heterogeneity 
was lower than 0.1, the DerSimonian-Laird’s estimator was used for the random-effect or fixed-
effect models when necessary. The Haploview version 4.2 software was used for calculation 
of haplotype associations. Power analyses were performed using the G*Power 3.1.3 software 
(http://www.psycho.uniduesseldorf.de).
RESULTS
The allele and genotype frequencies of the SNPs in STAT4 and IFIH1 in patients (T1D + 
AITD + CD, T1D only, and APSIII) and healthy controls are shown in Table 1. All polymorphisms 
were in Hardy-Weinberg equilibrium in all groups except the T1D only group. Distribution of STAT4 
and IFIH1 genotype and allele frequencies did not show statistically significant differences between 
patients and controls, indicating no association of the SNPs with development of T1D or APSIII 
regardless of the genetic model used. These results are shown in Table 2. Of note, the examined 
SNPs did not show linkage disequilibrium.
Furthermore, we performed a meta-analysis for the rs7574865 and rs1990760 SNPs from 
STAT4 and IFIH1, respectively. Including the present study, we gathered seven publications with 
data on the rs7574865 SNP (Lee et al., 2008; Martínez et al., 2008a; Zervou et al., 2008; Howson 
et al., 2011; Park et al., 2011; Bi et al., 2013) and ten for the rs1990760 SNP (Smyth et al., 2006, 
2008; Martínez et al., 2008b; Aminkeng et al., 2009; Jermendy et al., 2009; Liu et al., 2009; Schulte 
et al., 2010; Yang et al., 2012; Bouças et al., 2013; Zurawek et al., 2015). The total number of cases 
and controls was 1392 and 1629 for the rs7574865 SNP and 25,092 and 28,544 for the rs1990760 
SNP, respectively.
The forest plots of the meta-analyses of the rs7574865 and rs1990760 SNPs are shown 
in Figures 1 and 2, respectively. The rs7574865 (OR = 1.37; 95%CI = 1.23-1.52; P < 0.0001) 
and rs1990760 (OR = 0.85; 95%CI = 0.81-0.89; P < 0.0001) SNPs were both associated with 
T1D, although some moderate heterogeneity was detected (I² = 43.35%; P|Q| = 0.0478) for the 
rs1990760 SNP.
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Comparison  11 x 01 x 00   01 x 00     11 x 00    1 x 0
 P value OR 95%CI P value OR 95%CI P value OR 95%CI P value
rs7574865
   HC vs T1D 0.7737 1.04   (0.68-1.61) 0.9302 1.40   (0.56-3.51) 0.6320 1.11   (0.79-1.55) 0.6258
   HC vs T1D only 0.9753 0.95   (0.59-1.52) 0.9184 0.98   (0.34-2.87) 0.8095 0.97   (0.66-1.41) 0.9371
   HC vs APSIII 0.1864 1.38 (0.7-2.73) 0.4507 2.83   (0.86-9.25) 0.1570 1.54   (0.93-2.54) 0.1188
   T1D only vs APSIII 0.2038 1.46   (0.71-2.98) 0.3947 2.88   (0.8-10.34) 0.1910 1.59 (0.94-2.7) 0.1127
rs3024839         
   HC vs T1D ND 1.07     (0.09-23.29) 0.5067 ND ND ND 1.07 (0.07-17.12) 0.5073
   HC vs T1D only ND 1.44     (0.09-23.29) 0.6444 ND ND ND 1.44 (0.09-23.15) 0.6449
   HC vs APSIII ND 0.00 ND 0.4415 ND ND ND 0.00 ND 0.4420
   T1D only vs APSIII ND 0.00 ND 0.5812 ND ND ND 0.00 ND 0.5817
rs3747517         
   HC vs T1D 0.2983 0.87   (0.53-1.38) 0.6264 0.52 (0.22-1.2) 0.1821 0.80   (0.57-1.11) 0.2046
   HC vs T1D only 0.5700 0.85   (0.53-1.38) 0.6000 0.65   (0.27-1.55) 0.4438 0.83   (0.58-1.18) 0.3480
   HC vs APSIII 0.2176 0.93 (0.48-1.8) 0.9589 0.19   (0.02-1.49) 0.1519 0.72 (0.43-1.2) 0.2539
   T1D only vs APSIII 0.4346 1.09   (0.55-2.16) 0.9433 0.29   (0.04-2.43) 0.4108 0.86 (0.5-1.48) 0.6929
rs1990760          
   HC vs T1D 0.1037 0.70   (0.37-1.04) 0.1805 1.30   (0.69-2.45) 0.5124 1.04   (0.77-1.42) 0.8486
   HC vs T1D only 0.0688 0.62   (0.37-1.04) 0.0941 1.23   (0.63-2.43) 0.6645 0.99   (0.71-1.39) 0.9569
   HC vs APSIII 0.5943 0.98   (0.47-2.06) 0.8848 1.54   (0.59-4.01) 0.5259 1.19 (0.74-1.9) 0.5512
   T1D only vs APSIII 0.5036 1.58   (0.73-3.43) 0.3298 1.25   (0.48-3.24) 0.8351 1.19   (0.73-1.95) 0.5567
0 represents the less frequent allele and 1 is the most frequent; ND = not determined; OR = odds ratio; CI = confidence 
interval; HC = healthy control.
Table 2. Odds ratios, 95% confidence intervals, and P values from the association analysis between the STAT4 
(rs7574865 and rs3024839) and IFIH1 (rs3024839 and rs1990760) variants and type 1 diabetes (T1D) and 
autoimmune polyglandular syndrome type III (APSIII).
SNP                         HC                         T1D + AITD + CD                             T1D only                          APSIII
 N Freq. N Freq. N Freq. N Freq.
rs7574865
   G 294 0.77 260 0.75 197 0.78 63 0.68
   T   88 0.23   86 0.25   57 0.22 29 0.32
   GG 112 0.59   98 0.57   76 0.60 22 0.48
   GT   70 0.37   64 0.37   45 0.35 19 0.41
   TT     9 0.05   11 0.06     6 0.05   5 0.11
rs3024839
   T 353 1.00 331 1.00 245 1.00 86 1.00
   C     1 0.00     1 0.00     1 0.00   0 0.00
   TT 176 0.99 165 0.99 122 0.99 43 1.00
   TC     1 0.01     1 0.01     1 0.01   0 0.00
   CC     0 0.00     0 0.00     0 0.00   0 0.00
rs3747517
   C 230 0.68 249 0.72 179 0.72 70 0.74
   T 110 0.32   95 0.28   71 0.28 24 0.26
   CC   77 0.45   87 0.51   63 0.50 24 0.51
   CT   76 0.45   75 0.44   53 0.42 22 0.47
   TT   17 0.10   10 0.06     9 0.07   1 0.02
rs1990760
   C 202 0.61 201 0.60 150 0.61 51 0.57
   T 130 0.39 135 0.40   96 0.39 39 0.43
   CC   59 0.36   67 0.40   52 0.42 15 0.33
   CT   84 0.51   67 0.40   46 0.37 21 0.47
   TT   23 0.14   34 0.20   25 0.20   9 0.20
Table 1. Allele and genotype frequencies of the STAT4 (rs7574865 and rs3024839) and IFIH1 (rs3747517 and 
rs1990760) SNPs in type 1 diabetes mellitus patients (T1D only), T1D patients with autoimmune thyroid disease (AITD) 
and celiac disease (CD),  autoimmune polyglandular syndrome type III (APSIII) patients, and healthy controls (HC).
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DISCUSSION
Several T1D patients present simultaneously with autoimmune disorders and organ 
commitment. APSIII is the most common autoimmune disorder in T1D patients and is found more 
frequently in adults; it has low incidence in children. The individual pathogenic mechanisms underlying 
T1D, AITD, and CD remain unknown. Furthermore, it is unclear whether the development of these 
diseases is due to a shared common etiopathological mechanism or if it is just a consequence of 
the presence of one autoimmune disorder functioning as a trigger for the insurgence of another. 
The regulatory pathway of T cells might be a molecular target to understand the pathogenesis of 
APSIII due to the involvement of T cell activation in T1D, AITD and CD mechanisms. In addition, 
the role of viral infection and its related pathways may also be important in understanding the link 
between T1D, AITD, APSIII, and CD.
In this study, we assessed the role of STAT4 and IFIH1 variants in T1D and APSIII 
susceptibility. STAT4 is involved in Th1 regulation and its inhibition prevents the development of 
Figure 2. Forest plot from the meta-analysis for the SNP rs7574865 within the IFIH1.
Figure 1. Forest plot from the meta-analysis for the SNP rs7574865 within the STAT4.
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autoimmune diabetes in non-obese diabetic (NOD) mice. Moreover, genetic variants of STAT4 
are associated with autoimmune disorders in several populations, making STAT4 an emerging 
therapeutic target (Yang et al., 2004; Bi et al., 2013; Zheng et al., 2013). IFIH1 SNPs were first 
associated with T1D in autoimmune disease and have since been associated with other autoimmune 
systemic disorders. Upon viral infection, IFIH1 activates the IFN-I pathway and the release of IFN-I 
can activate STAT4, followed by the Th1 gene expression profile in mature dendritic cells (Kariuki 
et al., 2008). Herein, we investigated the individual and combined influence of STAT4 and IFIH1 
variants on T1D and APSIII development. In addition, we examined if STAT4 and IFIH1 SNPs are 
associated with development of T1D in a meta-analysis study.
The rs7574865 SNP is one of the most frequently examined polymorphisms in the STAT4 
gene and its function is related to gene expression on a transcriptional level and splice variation 
(Liang et al., 2012). The T allele of this particular SNP has been associated with multiple autoimmune 
disorders but the association is dependent on the population examined (Lee et al., 2010). In the 
present study, the SNPs examined from STAT4 and IFIH1 did not show any correlation (individually 
or combined) with incidence of T1D and/or APSIII. Although the rs7574865 SNP is within intron 3, 
it displays a linkage disequilibrium with other SNPs that have a possible functional consequence 
(Zheng et al., 2013). The rs3024839 SNP is an intragenic missense mutation (A > G resulting in 
isoleucine > valine substitution) with probable functional consequences in STAT4. Although STAT4 
SNPs have been frequently studied as potential indicators for autoimmune diseases, the results 
are still unclear, indicating that STAT4 might play varying roles in these disorders. Our results agree 
with the meta-analysis performed by Zheng et al. (2013), which revealed that the STAT4 rs7574865 
polymorphism is associated with several autoimmune diseases, including SLE, RA, scleroderma, 
systemic sclerosis (SSc), and primary SS, but is not associated with T1D, ulcerative colitis, and 
Crohn’s disease. Interestingly, SLE, RA, SSc, and SS are considered systemic disorders, whereas 
T1D is characterized as an organ-specific manifestation, which suggests that mutations in STAT4 
are primarily related to systemic rather than organ-specific disorders.
On the other hand, the study performed by Zervou et al. (2008) assessed the link between 
the rs7574865 SNP and risk of T1D in Crete, where there is a genetically homogenous population, 
and the results indicated that there was an association. Moreover, this polymorphism was strongly 
associated with T1D in a northeastern Chinese population (Bi et al., 2013). Additionally, the study 
performed by Fourati et al. (2012) assessed the possible role of non-HLA genes in APSII, which 
includes Addison’s disease and AITD and/or T1D, in a Tunisian population. Their results indicated 
that the rs7574865 SNP in STAT4 was associated with APSII but not with T1D or AITD alone, 
suggesting that STAT4 is involved with the co-occurrence of autoimmune endocrinopathies in 
APSII individuals.
IFIH1 is a helicase that senses viral dsRNA and, when activated, supports the transcription 
of IFN-I and IFN-induced genes (Robinson et al., 2011). Since IFIH1 acts during viral infections, 
we hypothesized in a previous publication that a defective mechanism in virus recognition might 
be caused by a defective IFIH1 (Moura et al., 2013). However, in the present study, we did not find 
any association between the rs3747517 (A > G resulting in histidine > arginine substitution in exon 
13) or rs1990760 (C > T resulting in alanine > threonine substitution in exon 15) SNPs in IFIH1 
and T1D or APSIII. Despite this, on including our data in the meta-analysis study, the rs1990760 
SNP in IFIH1 was found to be associated with T1D. The overexpression of IFIH1 in murine models 
is related to a chronic state of IFN-I production (Crampton et al., 2012). In multiple sclerosis (MS), 
which is an autoimmune disease, IFIH1 and Toll-like receptor 7 (TLR7) are overexpressed. TLR7 
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is associated with the IFN-I response and, consequently, the IFN signature (Hundeshagen et al., 
2012). The T allele in the rs1990760 SNP in IFIH1 is associated with increased expression of IFIH1 
in peripheral blood mononuclear cells and sensitivity to IFN-α (Rönnblom et al., 2011). Therefore, 
both STAT4 and IFIH1 exert some control in the IFN-I pathway, and their malfunction leads to an 
altered immune response.
In conclusion, we did not find any association of SNPs in STAT4 or IFIH1 with T1D 
development in a northeast Brazilian population. However, the meta-analysis showed an association 
between the rs7574865 and rs1990760 SNPs in STAT4 and IFIH1, respectively, with T1D, even 
when our negative associations were included.
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